Medtronic | MDT Stock Price, Company Overview & News (original) (raw)
Medtronic Plc is a medical technology company, which engages in the development, manufacture, distribution, and sale of device-based medical therapies and services. It operates through the following segments: Cardiac and Vascular Group; Minimally Invasive Technologies Group; Restorative Therapies Group; and Diabetes Group. The Cardiac and Vascular Group segment consist Cardiac Rhythm and Heart Failure, Coronary and Structural Heart, and Aortic and Peripheral Vascular divisions. The Minimally Invasive Technologies Group segment comprises Surgical Innovations and Respiratory, Gastrointestinal, an... Read More
Medtronic Plc is a medical technology company, which engages in the development, manufacture, distribution, and sale of device-based medical therapies and services. It operates through the following segments: Cardiac and Vascular Group; Minimally Invasive Technologies Group; Restorative Therapies Group; and Diabetes Group. The Cardiac and Vascular Group segment consist Cardiac Rhythm and Heart Failure, Coronary and Structural Heart, and Aortic and Peripheral Vascular divisions. The Minimally Invasive Technologies Group segment comprises Surgical Innovations and Respiratory, Gastrointestinal, and Renal divisions. The Restorative Therapies Group contains Spine, Brain, Specialty Therapies, and Pain Therapies divisions. The Diabetes Group segment focuses in the development, manufacturing, and marketing of products and services for the management of Type I and Type II diabetes. The company was founded in 1949 and is headquartered in Dublin, Ireland. Read Less
Industry
Health Care Equipment & Services
Founded
1949
Headquarters
Dublin
Country/Territory
Ireland
Chief Executive Officer
Geoffrey Straub Martha
Employees
95,000
Forbes Lists
#191
#386 - SALES
#241 - PROFITS
#435 - ASSETS
#129 - MARKET VALUE
Medtronic Financial Summary
Sources
FactSet, Bloomberg, S&P Cap IQ; Forbes.
SummaryAdditional DataAnalystsHistorical Quotes
Key Data
52 Week Range
75.96 x 92.68
Ex-Dividend Date
Dec 27, 2024
Valuation Measures
Price to Book Value (ttm)
2.25
Price to Tangible Book Value (ttm)
N/A
Total Enterprise Value to EBIT (ttm)
19.91
Total Enterprise Value to EBITDA (ttm)
13.77
Total Enterprise Value to Total Revenue (ttm)
3.94
Profitability Metrics
Operating Margin (ttm)
19.77%
Return on Assets (ttm)
4.53%
Return on Equity (ttm)
8.61%
Revenue and Earnings Metrics
Revenue Per Share (ttm)
25.25
Revenue Growth (y/o/y)
3.25%
EBITDA Growth (y/o/y)
4.26%
Diluted EPS Growth (y/o/y)
6.04
Cash and Debt Metrics
All values as of most recently reported quarter unless otherwise noted.
Consensus Recommendation
Outperform
Range of Price Targets
82.00 to 112.00
Range of Revenue 34Bto34B to 34Bto34.51B
- Consensus Price Target is the stock price analysts expect to see within a period of 0-18 months.
- EPS and Revenue estimates are for the next 12 months.
DATE | OPEN | HIGH | LOW | CLOSE | ADJUSTED CLOSE | VOLUME |
---|---|---|---|---|---|---|
Jan 14, 2025 | 83.39 | 85.31 | 83.11 | 85.25 | 85.25 | 12,690,639,000,000,000 |
Jan 13, 2025 | 80.91 | 82.12 | 80.01 | 81.79 | 81.79 | 6,487,705 |
Jan 10, 2025 | 82.00 | 82.49 | 80.51 | 80.66 | 80.66 | 7,068,239 |
Jan 8, 2025 | 80.41 | 83.22 | 80.35 | 82.68 | 82.68 | 11,154,164 |
Jan 7, 2025 | 80.37 | 81.07 | 79.74 | 79.87 | 79.87 | 7,363,342 |
Jan 6, 2025 | 80.52 | 81.14 | 79.66 | 79.84 | 79.84 | 7,886,375 |
Jan 3, 2025 | 80.50 | 81.00 | 79.98 | 80.95 | 80.95 | 5,394,979 |
Jan 2, 2025 | 80.37 | 80.67 | 79.86 | 80.22 | 80.22 | 5,575,206 |
Dec 31, 2024 | 79.82 | 80.23 | 79.38 | 79.88 | 79.88 | 4,803,813 |
Related People & Companies